1286279-29-5
1286279-29-5
Chemical Structure
BMS-813160
- CAS No.: 1286279-29-5
- Formula:C25H40N8O2
- Molecular Weight:484.64
IUPAC Name: N-((1R,2S,5R)-2-((S)-3-((7-(tert-butyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)-2-oxopyrrolidin-1-yl)-5-(tert-butylamino)cyclohexyl)acetamide
InChIKey: CMVHFGNTABZQJU-HCXYKTFWSA-N
SMILES: CC(N[C@H]1[C@@H](N2C([C@@H](NC3=NC=NC4=CC(C(C)(C)C)=NN43)CC2)=O)CC[C@@H](NC(C)(C)C)C1)=O
Biological Activity: BMS-813160 is a potent and selective CCR2/5 dual antagonist. BMS-813160 binds with CCR2 and CCR5 with IC50s of 6.2 and 3.6 nM, respectively. BMS-813160 can be used for the research of inflammation[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BMS-813160 | 99.93% | BMS-813160 is a potent and selective CCR2/5 dual antagonist. BMS-813160 binds with CCR2 and CCR5 with IC50s of 6.2 and 3.6 nM, respectively. BMS-813160 can be used for the research of inflammation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BMS-813160 (Standard) | ≥98% | BMS-813160 (Standard) is the analytical standard of BMS-813160 (HY-109593). This product is intended for research and analytical applications. BMS-813160 is a potent and selective CCR2/5 dual antagonist. BMS-813160 binds with CCR2 and CCR5 with IC50s of 6.2 and 3.6 nM, respectively. BMS-813160 can be used for the research of inflammation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BMS-741672 | BMS-741672 is a selective and orally active CCR2 antagonist with an IC50 of 1.1 nM. BMS-741672 shows >700-fold selective for CCR2 than CCR5. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BMS-681 | BMS-681 is an orthosteric antagonist of CC chemokine receptor 2 (CCR2). BMS-681 restricts the movement of the extracellular end of TM6 by stabilizing TM7. TM7 and TM6 are the main components of the orthosteric binding site. BMS-681 can be used to study inflammatory neurodegenerative diseases and cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BMS-753426 | BMS-753426 is a potent and orally bioavailable antagonist of CCR2. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SM-1295 | 98.71% | SM-1295 is an inhibitor of apoptosis protein (IAP) antagonist, with Kd values of 3077 nM, 3.2 nM and 9.5 nM for XIAP-BIR3, c-IAP1-BIR3 and c-IAP2-BIR3, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Xevinapant hydrochloride | 98.11% | Xevinapant (AT-406) hydrochloride is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). Xevinapant hydrochloride binds to XIAP, cIAP1, and cIAP2 proteins with Kis of 66.4, 1.9, and 5.1 nM, respectively. Xevinapant hydrochloride effectively antagonizes XIAP BIR3 protein in a cell-free functional assay, induces rapid degradation of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines. Xevinapant hydrochloride is highly effective in induction of apoptosis in xenograft tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CDK7-IN-8 | CDK7-IN-8 is a potent CDK7 inhibitor with IC50 of 54.29 nM. CDK7-IN-8 has inhibitory effect on certain cancer cells and in vivo tumor models. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lorundrostat | 99.33% | Lorundrostat (MT-4129) is an orally active aldosterone synthase inhibitor. Lorundrostat can be used in studies of high blood pressure. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Anagliptin hydrochloride | Anagliptin (SK-0403) hydrochloride is a highly selective, potent, orally active inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC50 of 3.8 nM, and less selective at DPP-8 and DDP-9 with IC50s of 68 nM and 60 nM, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Anagliptin (Standard) | ≥98% | Anagliptin (Standard) is the analytical standard of Anagliptin. This product is intended for research and analytical applications. Anagliptin (SK-0403) is a highly selective, potent, orally active inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC50 of 3.8 nM, and less selective at DPP-8 and DDP-9 with IC50s of 68 nM and 60 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BTK-IN-18 | BTK-IN-18 is a potent, reversible BTK inhibitor with an IC50 of 0.002 µM. BTK-IN-18 inhibits both CD69 and CD86 in vivo. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Norman P. et al. A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24. [Content Brief]
- [2]. Cherney RJ, et al. BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate. ACS Med Chem Lett. 2021 Oct 15;12(11):1753-1758. [Content Brief]
